(Taipei Taiwan, May 16, 2022) Pharmosa Biopharm Inc. today announces the presentation of P204/A8350 Poster at 2022 American Thoracic Society (ATS) Conference at San Francisco, CA., titled as “Multicompartment Modeling for Pulmonary Pharmacokinetics of Liposomal Treprostinil (L606) in Adults.
PBI’s multicompartment physiologically-based model was developed to simulate treprostinil levels of L606 and Tyvaso in the pulmonary tissue of healthy adult volunteers. Currently in the market, inhaled treprostinil is delivered with immediate-release formulation. Short half-life results in high peak-trough fluctuation and requires frequent dosing.
Important data derived from this modelling includes:
- Inhaled liposomal treprostinil (L606) provides extended release and stable plasma concentration as demonstrated in healthy adult volunteers. In PK-PD animal study, L606 indicated 12-hour extended PAP reduction while the same dose of free solution lasted only for 4 hours.
- The result from PBI’s Multicompartment Modeling indicates that L606 in pulmonary tissues is at approx. 1.0 ng/mL and lasts for at least 10 hours. It is about 10 times higher than plasma concentration. Comparatively, Treprostinil in ELF is absorbed rapidly due to high permeability, reaching the maximum concentration in pulmonary tissue, then dropping quickly and equilibrating with plasma compartment within 2 hours.
- The experiment concludes that the multicompartment physiologically-based model provides a quantitative simulation of Treprostinil level in pulmonary tissue. It indicates the potential of L606 for extended pharmacological effect at the equivalent dose as Tyvaso. L606 is currently undergoing phase III pivotal trial in US.
Disclaimer: Drug development timeline is often long and with uncertainties, many of which are beyond our control. The information contained herein does not constitute a solicitation of any securities. For corporate development and filings, please refer to Taiwan MOPs for public information disclosures.
